Kingsway Biotechnology (01548): Legendary announced at the 2026 EHA Annual Meeting the latest groundbreaking oral presentation showing preliminary Phase 1 data of LB2501 for NHL in vivo CAR-T.

The Zhitong Finance APP reports that Kingsway Group's biological technology (01548) has announced that its affiliate company, Legend BioTech Limited (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares), submitted a 6-K form to the US Securities and Exchange Commission (SEC) and issued a press release on June 2, 2026 (New York time) (after the Hong Kong trading session on June 2, 2026), announcing that the preliminary clinical data of its in-house CD19/CD20 dual-target CAR-T cell therapy LB2501 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) has shown positive signals. The data will be reported at the latest breakthrough session of the 2026 European Hematology Association (EHA) annual meeting, which will be held in Stockholm, Sweden from June 11 to June 14, 2026.